Loading...
Market
Will Ozempic's market share in Brazil decrease by 5% by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports and sales data published by industry analysts
Story
Anvisa Approves EMS Production of Liraglutide Medications Lirux and Olire, First Competitor to Ozempic, for Sale in 2025
Dec 24, 2024, 02:11 PM
The Brazilian Health Regulatory Agency (Anvisa) has approved the production of two liraglutide-based medications by the pharmaceutical company EMS. The drugs, named Lirux and Olire, are intended for the treatment of type 2 diabetes and obesity, respectively. This marks the introduction of the first national competitor to Ozempic, a medication widely used for similar purposes. The approval was officially published in the Diário Oficial on December 23, 2024, and the medications are expected to be available for commercial sale in 2025. In a separate development, Anvisa has prohibited a supplement that falsely claimed to cure diabetes, which had been linked to misleading information about the disease.
View original story
Similar markets
Neutral • 25%
Highly positive • 25%
Negative • 25%
Somewhat positive • 25%
Other regulatory actions • 25%
Safety label update • 25%
Product recall • 25%
No action taken • 25%
Less than 30% • 25%
More than 50% • 25%
40% to 50% • 25%
30% to 40% • 25%
FDA approved and in market • 25%
Rejected by FDA • 25%
Pending approval • 25%
Withdrawn by manufacturer • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Yes • 50%
No • 50%
No decision made • 25%
Approve distribution city-wide • 25%
Approve limited distribution • 25%
No distribution approved • 25%